Covered recipient · General Payments record
MICHAEL J OLIVER
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$2,982.16
111 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,790.64 | 102 |
| Travel and Lodging | $1,183.17 | 8 |
| Education | $8.35 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $1,795.31 | 30 |
| Novo Nordisk Inc | $425.19 | 25 |
| GlaxoSmithKline, LLC. | $136.97 | 13 |
| SANOFI-AVENTIS U.S. LLC | $72.86 | 6 |
| Amarin Pharma Inc. | $71.06 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $68.76 | 5 |
| Allergan Inc. | $67.86 | 4 |
| Amgen Inc. | $57.78 | 3 |
| PFIZER INC. | $39.99 | 3 |
| Novartis Pharmaceuticals Corporation | $29.81 | 2 |
| Merck Sharp & Dohme Corporation | $29.38 | 2 |
| AstraZeneca Pharmaceuticals LP | $26.33 | 2 |
| Janssen Pharmaceuticals, Inc | $24.90 | 2 |
| Radius Health, Inc. | $21.00 | 1 |
| Lilly USA, LLC | $19.47 | 2 |
| Genentech USA, Inc. | $15.76 | 1 |
| Corcept Therapeutics | $14.60 | 1 |
| Kowa Pharmaceuticals America, Inc. | $13.82 | 1 |
| AbbVie, Inc. | $13.53 | 1 |
| Gilead Sciences, Inc. | $13.43 | 1 |
| Nalpropion Pharmaceuticals LLC | $12.83 | 1 |
| E.R. Squibb & Sons, L.L.C. | $11.52 | 1 |
Page 1 of 3; records 1–50 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL J OLIVER
NPI 1679501431 · CMS profile ID 121491
Allopathic & Osteopathic Physicians / Internal Medicine
BEAVER, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 3; records 1–50 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679501431?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501431?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501431?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 111 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1679501431?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
111 matching records · $2,982.16 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 111.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $0.73 | 12/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670503759 | CMS |
| GlaxoSmithKline, LLC. | $9.08 | 12/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671542107 | CMS |
| Amarin Pharma Inc. | $15.98 | 12/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699277561 | CMS |
| Novo Nordisk Inc | $12.15 | 12/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674710060 | CMS |
| Novo Nordisk Inc | $14.76 | 12/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674710047 | CMS |
| Amgen Inc. | $21.46 | 12/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662782875 | CMS |
| Kowa Pharmaceuticals America, Inc. | $13.82 | 11/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 630290715 | CMS |
| Novo Nordisk Inc | $16.80 | 11/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674710043 | CMS |
| Novo Nordisk Inc | $13.77 | 11/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674710051 | CMS |
| Novo Nordisk Inc | $17.11 | 11/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674710039 | CMS |
| Novartis Pharmaceuticals Corporation | $11.18 | 11/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659882919 | CMS |
| GlaxoSmithKline, LLC. | $15.21 | 11/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671025315 | CMS |
| Novo Nordisk Inc | $12.59 | 11/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674710055 | CMS |
| SANOFI-AVENTIS U.S. LLC | $11.19 | 10/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694184279 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11.14 | 10/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700184467 | CMS |
| GlaxoSmithKline, LLC. | $15.97 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671470879 | CMS |
| PFIZER INC. | $12.99 | 10/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673212083 | CMS |
| Novo Nordisk Inc | $124.99 | 10/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703529621 | CMS |
| PFIZER INC. | $14.22 | 10/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673206043 | CMS |
| Novo Nordisk Inc | $15.43 | 10/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674988761 | CMS |
| Novo Nordisk Inc | $14.43 | 09/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674553803 | CMS |
| Allergan Inc. | $23.52 | 09/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670899283 | CMS |
| GlaxoSmithKline, LLC. | $10.56 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670939323 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.78 | 08/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700184469 | CMS |
| SANOFI-AVENTIS U.S. LLC | $12.34 | 08/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694136653 | CMS |
| Novo Nordisk Inc | $12.64 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 690067873 | CMS |
| Novo Nordisk Inc | $0.62 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 690067905 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.36 | 08/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700184471 | CMS |
| Novo Nordisk Inc | $4.24 | 08/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682827239 | CMS |
| Novo Nordisk Inc | $17.07 | 08/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674592963 | CMS |
| Novo Nordisk Inc | $0.31 | 08/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682827249 | CMS |
| Amarin Pharma Inc. | $18.52 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699195573 | CMS |
| SANOFI-AVENTIS U.S. LLC | $11.50 | 07/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694118321 | CMS |
| Lilly USA, LLC | $8.35 | 07/19/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658027441 | CMS |
| Novo Nordisk Inc | $15.48 | 07/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674484229 | CMS |
| Gilead Sciences, Inc. | $13.43 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681576245 | CMS |
| Novo Nordisk Inc | $14.43 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 674484233 | CMS |
| GlaxoSmithKline, LLC. | $10.06 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671287597 | CMS |
| GlaxoSmithKline, LLC. | $14.49 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671460303 | CMS |
| Allergan Inc. | $14.14 | 06/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670899281 | CMS |
| Merck Sharp & Dohme Corporation | $17.35 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695706751 | CMS |
| Eli Lilly and Company | $44.55 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709011079 | CMS |
| Eli Lilly and Company | $4.64 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709011081 | CMS |
| Eli Lilly and Company | $1.86 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709011083 | CMS |
| Eli Lilly and Company | $2.23 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013085 | CMS |
| Eli Lilly and Company | $81.67 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013087 | CMS |
| Eli Lilly and Company | $18.56 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013487 | CMS |
| Eli Lilly and Company | $33.41 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013489 | CMS |
| Eli Lilly and Company | $104.78 | 06/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013835 | CMS |
| Eli Lilly and Company | $3.34 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013837 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,083,959.47 | 12 |
| PY2024 | Recipient | $43,914.50 | 5 |
| PY2024 | Principal investigator | $1,015,962.54 | 15 |
| PY2023 | Recipient | $195.00 | 1 |
| PY2023 | Principal investigator | $828,848.21 | 14 |
| PY2022 | Recipient | $34,661.00 | 4 |
| PY2022 | Principal investigator | $514,412.47 | 14 |
| PY2021 | Principal investigator | $507,716.92 | 33 |
| PY2020 | Recipient | $5,278.97 | 8 |
| PY2020 | Principal investigator | $291,944.00 | 17 |
| PY2019 | Recipient | $10,899.97 | 2 |
| PY2019 | Principal investigator | $442,530.95 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
33 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $72,557.00 | 08/26/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 819466633 |
| Principal investigator 1 | Eli Lilly and Company | $47.50 | 05/31/2021 | Non-covered Recipient Entity GCM MEDICAL GROUP PSC | A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 819460743 |
| Principal investigator 1 | Eli Lilly and Company | $7.50 | 05/25/2021 | Non-covered Recipient Entity MILLENNIUM RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | No dispute reported | 06/30/2026 | 819461377 |
| Principal investigator 1 | Eli Lilly and Company | $7.50 | 05/25/2021 | Non-covered Recipient Entity STACY SMITH MD APC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | No dispute reported | 06/30/2026 | 819466407 |
| Principal investigator 1 | Eli Lilly and Company | $15.30 | 05/10/2021 | Non-covered Recipient Entity CLINICAL RESEARCH PROFESSIONALS LLC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819454431 |
| Principal investigator 1 | Eli Lilly and Company | $94.50 | 05/10/2021 | Non-covered Recipient Entity COVANCE CLINICAL RESEARCH UNIT INC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819455465 |
| Principal investigator 1 | Eli Lilly and Company | $63.00 | 05/10/2021 | Non-covered Recipient Entity COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819456613 |
| Principal investigator 1 | Eli Lilly and Company | $30.60 | 05/10/2021 | Non-covered Recipient Entity ENCOMPASS CLINICAL RESEARCH | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819458725 |
| Principal investigator 1 | Eli Lilly and Company | $63.00 | 05/10/2021 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819462947 |
| Principal investigator 1 | Eli Lilly and Company | $25.50 | 05/10/2021 | Non-covered Recipient Entity PALM RESEARCH CENTER INC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819465997 |
| Principal investigator 1 | Eli Lilly and Company | $7.65 | 05/10/2021 | Non-covered Recipient Entity RESEARCH FOUNDATION OF STATE UNIV OF NY | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819466317 |
| Principal investigator 1 | Eli Lilly and Company | $51.00 | 05/10/2021 | Non-covered Recipient Entity PROGRESSIVE MEDICAL CONCEPTS LLC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819467649 |
| Principal investigator 1 | Eli Lilly and Company | $30.60 | 05/10/2021 | Non-covered Recipient Entity TEXAS DIABETES AND ENDOCRINOLOGY PA | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819469765 |
| Principal investigator 1 | Eli Lilly and Company | $22.95 | 05/10/2021 | Non-covered Recipient Entity WEILL MEDICAL COLLEGE | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819470953 |
| Principal investigator 1 | Eli Lilly and Company | $3,349.37 | 05/03/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819466529 |
| Principal investigator 1 | Eli Lilly and Company | $47.50 | 04/30/2021 | Non-covered Recipient Entity DERMATOLOGY ASSOCIATES OF PLYMOUTH MEETING PC | A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 819456559 |
| Principal investigator 1 | Eli Lilly and Company | $50.00 | 04/30/2021 | Non-covered Recipient Entity RENSTAR MEDICAL RESEARCH | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | No dispute reported | 06/30/2026 | 819466301 |
| Principal investigator 1 | Eli Lilly and Company | $5,299.57 | 04/15/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 819466527 |
| Principal investigator 1 | Eli Lilly and Company | $42.50 | 04/08/2021 | Non-covered Recipient Entity ACCURATE CLINICAL MANAGEMENT LLC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819450853 |
| Principal investigator 1 | Eli Lilly and Company | $735.00 | 04/08/2021 | Non-covered Recipient Entity LCGK RSRCH | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819462807 |
| Principal investigator 1 | Eli Lilly and Company | $45.90 | 04/08/2021 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819470105 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,148.73 | 04/02/2021 | Non-covered Recipient Entity HERITAGE VALLEY MEDICAL GROUP INC | A 28-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 809486295 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $68,082.65 | 02/05/2021 | Non-covered Recipient Entity Heritage Valley Multispecialty Group | Phase II study of BI456906 in Patients with T2DM O | No dispute reported | 06/30/2026 | 840491149 |
| Principal investigator 1 | Eli Lilly and Company | $252.20 | 01/29/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | No dispute reported | 06/30/2026 | 819466525 |
| Principal investigator 1 | Eli Lilly and Company | $102.25 | 01/29/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 819468799 |
| Principal investigator 1 | Eli Lilly and Company | $475.54 | 01/29/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 819468801 |
| Principal investigator 1 | Eli Lilly and Company | $100.00 | 01/29/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 819468929 |
| Principal investigator 1 | Eli Lilly and Company | $5,813.05 | 01/12/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 819468281 |
| Principal investigator 1 | Eli Lilly and Company | $20,107.00 | 01/12/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | No dispute reported | 06/30/2026 | 819469895 |
| Principal investigator 1 | Eli Lilly and Company | $929.00 | 01/05/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 819468027 |
| Principal investigator 1 | Eli Lilly and Company | $191,775.00 | 01/05/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 819468029 |
| Principal investigator 1 | Eli Lilly and Company | $125,548.00 | 01/05/2021 | Non-covered Recipient Entity TRI STATE MEDICAL GROUP INC | A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | No dispute reported | 06/30/2026 | 819468279 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,790.06 | 01/01/2021 | Non-covered Recipient Entity Heritage Valley Multispecialty Group | Phase II study of BI456906 in Patients with T2DM O | No dispute reported | 06/30/2026 | 840494171 |